This Week In Hearing:
Peter Markham & Celia Belline discuss
New Medical Approaches to Treating Hearing Loss
In this interview with Hearing Health Matters, Celia Belline, CILcare founder and CEO, and Peter Markham, CBSET founder, CEO and President, recount their successful strategic collaboration over the last 5 years, and their recent award for their innovative preclinical auditory services in the 3rd Annual Hearing Technology Innovator Awards.
Auditory Efficacy and Safety Services from CBSET & CILcare
CBSET and a premier CRO specializing in hearing, CILcare, have created a strategic alliance to offer a broad range of cutting-edge preclinical services for the assessment of drugs, medical devices, and gene and cell-based therapies for auditory functions in a GLP-compliant environment.
Extensive History in Otology Research
Based on an extensive history in basic and clinical otology research, we provide a broad range of in vivo models, enabling studies from proof-of-concept and non-GLP programs through fully GLP-compliant safety assessments. Inner ear and systemic pharmacokinetics, ototoxicity, and safety and efficacy studies may be conducted in a variety of preclinical species and models including device-mediated therapy (such as cochlear implants and implantable drug delivery systems), biologics and therapeutic proteins, small molecules, cell products, or gene therapy vectors, all in accordance with best practices and applicable regulatory guidelines.
A Broad Range of Technical Capabilities for Auditory Therapy Assessment
Our technical capabilities include in-life assessment with high-throughput electrophysiological measurements and post-mortem assessments via immunohistochemistry, histopathology, and hair cell and ribbon synapse quantification. In addition, our otic research scientists and surgeons can provide method development support to adapt or replicate challenging technical procedures including cochleostomy, canalostomy, and round window injections targeting different sites of interest.
- Expertise in auditory assessment
- ABR (Auditory Brainstem Response) measurements
- Otoscopic evaluation
- Ribbon synapses counting
- Histopathology and immunohistochemistry
- Cochlear explants
- Animal models
- Drug-induced ototoxicity
- Otitis media
- Animal species
- Guinea pigs
- Routes of delivery
- Round window
- Perilymph & cochlea
- Tympanic bulla
- CSF and other tissues
ABR are electric potentials recorded from scalp electrodes. This non-invasive method allows determination of auditory response thresholds. It is translational between rodents and humans, and is commonly used for screening newborns.
The cytocochlelogram allows histopathological assessment of ototoxic damage on inner hair cell and outer hair cell of the cochlea, with anatomical localization corresponding to predicable patterns of functional deficits.